Homonymous hemianopia: challenges and solutions.
Denise Goodwin
https://pubmed.ncbi.nlm.nih.gov/25284978/Actively Recruiting
Led by NeuroAEye LLC · Updated on 2026-04-02
20
Participants Needed
2
Research Sites
4 weeks
Total Duration
Researchers are evaluating the PAVE Parallactic Visual-Field Enhancement System for treating chronic visual field loss caused by stroke, traumatic brain injury, or brain surgery. This study focuses on patients with homonymous hemianopia, quadrantanopia, or general visual field constriction at least six months and up to ten years after brain injury. The goal is to measure improvement in visual field size and subjective visual function after PAVE therapy. The treatment involves using a virtual reality headset to deliver visual stimulation through the PAVE software. Participants will complete three therapy sessions per week for eight weeks, each session consisting of two seven-minute visual stimulation periods separated by a short break. The study includes baseline, mid-therapy week 4, end-of-therapy week 8, and follow-up week 12 visits for visual field assessments and questionnaires. Participants will visit the research office at the start, week 4, week 8, and week 12 for visual field measurements using Goldmann-type kinetic perimetry and to complete the National Eye Institute Visual Function Questionnaire. The study tracks changes in visual field area as the primary outcome and the proportion of participants showing improvement as a secondary outcome. The total participation duration is 12 weeks, including therapy and follow-up assessments.
CONDITIONS
PAVE (Parallactic Visual-Field Enhancement) System for Treatment of Chronic Visual Field Loss Due to Stroke, Traumatic Brain Injury, or Brain Surgery
M
Michael Lynch, BSME
P
Paige Clinical Study Coordinator
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
NeuroAEye LLC
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | PAVE Therapy (Investigational) | Vision Restoration Therapy (Current Rehabilitation Practice) |
|---|---|---|
| What it is | A visual rehabilitation therapy using a virtual reality head mounted display, designed for adults with chronic visual field loss after stroke, traumatic brain injury, or brain surgery. | Vision restoration therapy (VRT) is a computer-based visual stimulation program used to promote visual field recovery in adults with chronic homonymous visual field defects following brain injury. |
| Role in trial | Tested intervention in a single-group clinical trial evaluating feasibility and effect on visual field area. | External comparator representing current practice in visual rehabilitation for chronic visual field loss. |
| Primary use | Intended to improve visual field area in people with chronic homonymous hemianopsia or quadrantanopia caused by cerebrovascular accident, traumatic brain injury, or brain surgery. | Used to attempt to restore visual field in adults with chronic visual field defects from brain injury, often with the goal of improving functional vision. |
| How it is given or performed | Participants receive visual stimulation through a virtual reality headset, three times per week, each with two 7-minute sessions separated by at least one minute, plus visual field assessments before and after therapy. | Computer-based training, usually performed at home or in a clinical setting, typically involves daily visual stimulation exercises lasting around 30–60 minutes each day over several months. |
| Evidence status | Currently under evaluation; clinical trial results not yet reported. | Multiple studies and reviews report small to moderate average visual field improvements after VRT in some patients, though variability in outcome and methodological limitations are noted. |
| Important limitations | Evidence is limited to feasibility and early clinical outcome data; no published randomized controlled trials or large-scale results for this device in the target population. | Published studies have shown variable patient responses, limited sample sizes, methodological concerns, and carry a risk of bias. Functional significance and generalizability may be limited. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 8 weeks
Participants receive therapy using the PAVE software on a virtual reality head mounted display. Treatment involves visual stimulation sessions three times per week for eight weeks, with each session including two 7-minute therapy periods separated by a short break. Visual field assessments are performed before and after therapy sessions.
Three visits per week for 8 weeks
Duration - 4 weeks
Participants return for assessments to evaluate changes in visual field area and visual performance after completing treatment.
Visits at week 12 after treatment start
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Denise Goodwin
https://pubmed.ncbi.nlm.nih.gov/25284978/Ava K Bittner, Mian Haris Iftikhar, Gislin Dagnelie
https://pubmed.ncbi.nlm.nih.gov/21896857/J Pe'er, G Zajicek, I Barzel
https://pubmed.ncbi.nlm.nih.gov/6848135/Lies Bouwmeester, Joost Heutink, Cees Lucas
https://pubmed.ncbi.nlm.nih.gov/17135455/Claire S Barnes, Ronald A Schuchard, David G Birch...
https://pubmed.ncbi.nlm.nih.gov/31211001/E Kasten, B A Sabel
https://pubmed.ncbi.nlm.nih.gov/21551894/Carolin Gall, Iris Mueller, Julia Gudlin...
https://pubmed.ncbi.nlm.nih.gov/18997310/William V Padula, Jose E Capo-Aponte, William V Padula...
https://pubmed.ncbi.nlm.nih.gov/28440687/Dorothe A Poggel, Iris Mueller, Erich Kasten...
https://pubmed.ncbi.nlm.nih.gov/20871147/John B Christoforidis
https://pubmed.ncbi.nlm.nih.gov/21573042/NeuroAEye LLC
Lead Sponsor